Chronogen Inc.

Industry: Pharmaceuticals, Biotechnology
Chronogen Inc., a privately-held drug discovery company, is a leader in the identification of targets that control the degenerative processes of aging. Based on this innovative approach, the company is developing novel products to control lipid and oxidative stress levels, which are established disease mechanisms in cardiovascular disorders. The control of aging in whole model organisms has provided very valuable assets for a drug discovery technology that will lead to novel and efficacious drugs in significant markets including atherosclerosis, vascular complications of diabetes, and ischemia/reperfusion injuries. Chronogen is headquartered in Montreal, Canada. ( www.chronogen.com )

Chronogen Inc.
2901 Rachel E. Suite 22
Montreal, Quebec H1W 4A4
Canada

Tel: (514) 521-9595
Fax: (514) 521-1579

Aventis-Pasteur , Inc.

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Aventis Pasteur, the vaccines business of Aventis, in 2002, produced 1.4 billion doses of vaccine, making it possible to protect 500 million people across the globe, which is about 1.4 million per day. The company offers the broadest range of vaccines, providing protection against 20 bacterial and viral diseases. ( www.aventispasteur.com )

Aventis-Pasteur , Inc.
1755 Steeles Avenue West
Toronto, Ontario M2R 3T4
Canada

Tel: (416) 667-2955
Fax: (416) 667-2900

Network Immunology Inc.

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Network Immunology Inc. is a vaccine company. The company’s focus is to commercialize a preventive HIV vaccine invented in 2005 by Dr. Geoffrey W. Hoffmann, the Chief Scientist of the company. The Network Immunology vaccine is for HIV negative persons. The technology is based on a theory of AIDS pathogenesis developed by Dr. Hoffmann (G. W. Hoffmann (1994) Co-selection in immune network theory and in AIDS pathogenesis, Immunology and Cell Biology, 72, 338-346). A key postulate of the theory was validated in a paper published eight years later (D. C. Douek et al. (2002) HIV preferentially infects HIV-specific CD4+ T cells. Nature, 417, 95-98). The global demand for an HIV/AIDS vaccine ia ( www.networkimmunologyinc.com )

Network Immunology Inc.
200 – 2386 East Mall #6
Vancouver, British Columbia V6T 1Z3
Canada

Tel: (604) 222-3605

LymphoSign Inc.

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
LymphoSign is developing a number of novel compounds discovered in the laboratory of Dr. Chaim Roifman, the company’s founder, at The Hospital for Sick Children, Toronto. These compounds inhibit abnormal cellular signalling specific to the growth of cancer cells. LymphoSign’s lead drug candidate LS104 is nearing completion of pre-clinical testing and has shown great promise as a potential treatment of acute leukemias (ALL and AML) as well as other cancers. LS104 has demonstrated very low or no toxicity toward normal cells. The Cancer Therapeutic Landscape is Changing: The worldwide market for cancer therapeutics is approaching US$15 billion in annual sales. Ten years ago, generic cancer drugs were a substantial portion of a much smaller ( www.lymphosign.com )

LymphoSign Inc.
675 Cochrane Drive 6Th Floor
East Tower Markham, Ontario L3R 0B8
Canada

Tel: (905) 530-2333

Amorfix Life Sciences Ltd.

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Amorfix is an emerging theranostics company focused on the diagnosis and treatment of neurodegenerative diseases, where aggregated misfolded proteins (AMP) are prevalent. These include Transmissible Spongiform Encephalopathies (TSE), such as Bovine Spongiform Encephalopathy (BSE) and the human form variant Creutzfeldt-Jakob Disease (vCJD), as well as degenerative diseases such as Alzheimer’s Disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s Disease (PD). The company was formed in January 2004 to commercialize the discoveries of the epitope protection (EP) technologies at the University of Toronto discovered by Drs. Neil Cashman and Marty Lehto. These discoveries position the company to become the world authority on AMP ( www.amorfix.com )

Amorfix Life Sciences Ltd.
3080 Yonge St. Suite 6020
Toronto, Ontario M4N 3N1
Canada

Tel: (416) 482-3814
Fax: (416) 482-3811

ImmunoVaccine Technologies Inc.

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
ImmunoVaccine Technologies Inc. (IVT) is a biotechnology research company based in Halifax, Nova Scotia, Canada. We are currently commercializing novel innovative vaccine technology featuring a unique liposome-based formulation that provides an enhanced immune response following a single administration. We currently have an opportunity for a Microbiology/Immunology Technician. The successful candidate will have a M. Sc. in one or more of the following disciplines: microbiology, immunology, cell biology, molecular biology, or biochemistry with relevant lab experience (minimum 1 ( www.immunovaccine.com )

ImmunoVaccine Technologies Inc.
1819 Granville Street Suite 303
Halifax, Nova Scotia B3J 3R1
Canada

Tel: (902) 492-1819
Fax: (902) 492-0888

Ellipsis Biotherapeutics Corporation

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
About Ellipsis: Ellipsis is a privately held drug discovery company with lead candidates in the diagnosis and treatment of Degenerative Neurologic Disorders, specifically Alzheimer’s Disease. In addition, the company has discovery programs in Inflammatory Diseases, including Inflammatory Bowel Disease and Rheumatoid Arthritis. Ellipsis’ central business strategy is to develop therapeutics and diagnostics through early clinical proof (Phase I/II of clinical trials) and partner downstream commercialization and marketing. With future projects, Ellipsis intends to retain the rights to identified compounds through later stages of the discovery and clinical trials process before seeking commercialization ( www.ellipsis.com )

Ellipsis Biotherapeutics Corporation
700 Bay Street Suite 2101, Box 195
Toronto, Ontario M5G 1Z6
Canada

Tel: (416) 586-0281
Fax: (416) 586-0638

Allon Therapeutics Inc.

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Allon Therapeutics Inc. is a Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as Alzheimer’s disease, mild cognitive impairment, stroke, traumatic brain injury, multiple sclerosis and neuropathy. The Company is listed on the Toronto Stock Exchange under the trading symbol “NPC” (Neuro Protection Company) and based in Vancouver. ( www.allontherapeutics.com )

Allon Therapeutics Inc.
506 1168 Hamilton Street
Vancouver, British Columbia V6B 2S2
Canada

Tel: (604) 736-0634
Fax: (604) 736-1616